Parallax Health Sciences, Inc. (OTCMKTS: PRLX) is a development-stage biotechnology company specializing in the research, development and commercialization of proprietary peptide-based products and therapies. The company focuses on applications in regenerative medicine, cosmeceuticals and nutraceuticals, aiming to harness peptide analogs for tissue repair, anti-aging and inflammation modulation.
Parallax Health Sciences’ pipeline includes peptide candidates designed for wound healing, joint health, skin rejuvenation and related indications. The company collaborates with contract development and manufacturing organizations to advance preclinical research and pursue regulatory approvals in the United States and select global markets.
Headquartered in Orlando, Florida, Parallax Health Sciences maintains an intellectual property portfolio covering its core peptide technologies. The company pursues strategic alliances across pharmaceutical, cosmetic and nutraceutical sectors to position its lead candidates for clinical development and eventual market commercialization.
Shares of the company trade on the OTC Markets under the symbol PRLX. Parallax Health Sciences is led by an experienced management team with expertise in biotechnology research, regulatory strategy and commercial operations, and continues to explore collaborative research agreements and licensing opportunities to expand its reach across North America, Europe and Asia–Pacific.
AI Generated. May Contain Errors.